Johnson and Johnson Merck Consumer Pharmaceuticals News
News on Johnson and Johnson Merck Consumer Pharmaceuticals continually updated from thousands of sources around the net.
2 hrs ago | Sys-Con Media
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Whose policies do more to help the poor?
Can You Crack These Presidential Code Names?
3 hrs ago | Stock Market Review
In a court filing by a patients attorney in West Virginia on December 2, Johnson & Johnson officials of J&J's Ethicon unit, makers of Gynecare Prolift implant, lost or disposed of potentially hundreds of thousands of documents over a decade even though they were ordered by executives to preserve them.
The firm currently has a $61.00 target price on the stock, up from their previous target price of $45.00.
Under the new agreement, USMI will begin shipping product to Chesapeake Surgical for distribution starting in 2014.
Aisling Capital is a private-equity firm. It makes investments in product acquisitions, positioning companies, follow-on financings, and industry consolidations.
Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
The report from Toronto-based Environmental Defence says the big five all have issues with chemicals that could be harmful to human health, but some are doing better than others.
Johnson & Johnson officials destroyed or misplaced documents related to its vaginal-mesh implants and should be barred from relying on some defenses in planned trials over the devices, patients' lawyers said.
Microsoft Corp. sold $8 billion of bonds in dollars and euros, a record offering from the world's largest software maker that followed Johnson & Johnson by issuing AAA rated corporate securities this week.
But can 2014 keep up with the sort of returns that 2013 delivered? ) , it's a question of how this Dow health care staple can rebound from the patent cliff's withering effects on sales.
In this series, our goal is to develop a diversified health care virtual portfolio that provides returns above and beyond the S&P 500.
Johnson & Johnson and Bayer's drug Xarelto generated $246 million in sales in the third quarter, while sales of Eliquis from Pfizer and Bristol-Myers Squibb were $41 million for the same period.
Micro plastics are some of the worst water pollutants; they not only harm the local wildlife, but also accumulate into fish that humans consume and cause major health problems.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .
Johnson & Johnson may sell bonds maturing in three, five, 10, 20 and 30 years. CEO Alex Gorsky, in photo above, has helped maintain its top credit ranking despite recent multibillion-dollar settlements over faulty products.
Good roundup from John Lynch in this morning's D-G on the $1.2 billion fine imposed by Circuit Judge Tim Fox in April of 2012 after a jury found Johnson & Johnson liable for Medicaid fraud over the marketing of the anti-psychotic drug Risperdal .